ECE2017 Eposter Presentations: Pituitary and Neuroendocrinology Growth hormone IGF axis - basic (10 abstracts)
Somatropin treatment Supported by NHS: characterization of submitted patients – 2006 to 2016
Margarida Bastos 1, , Alice Mirante 1, , Caldas Afonso 1, , Carlos Vasconcelos 1, , Conceição Bacelar 1, , Conceição Pereira 1, , Lurdes Lopes 1, , Marcelo Fonseca 1, , Joana Serra-Caetano 2 , Miguel Patrício 1, , Cesar Marques Esteves 1, , Florbela Ferreira 1, , Graciete Bragança 1, , Luísa Raimundo 1, , Lurdes Matos 1, , Lurdes Sampaio 1, , Manuel Fontoura 1, & Teresa Borges 1,
1Comissão Nacional para a Normalização da Hormona de Crescimento (CNNHC), Portugal, Portugal; 2Endocrinology and Pediatric Endocrinology Departments of: CH Universitário de Coimbra, Coimbra, Portugal; 3CH Porto, Porto, Portugal; 4CH Lisboa Ocidental, Lisboa, Portugal; 5Oncology Portuguese Institute Francisco Gentil, Lisboa, Portugal; 6CH Lisboa Central, Lisboa, Portugal; 7Unidade ULSM, Matosinhos, Portugal; 8CH Lisboa Norte, Lisboa, Portugal; 9H Fernando Fonseca, Amadora, Portugal; 10CH Garcia de Horta, Almada, Portugal; 11CH S. João, Porto, Portugal; 12L. Biostatistics and MI and IBILI, FMC, U Coimbra, Coimbra, Portugal.
Introduction: In our country somatropin treatment is supported by the National Health Service. A National Committee (CNNHC) rules and analysis the submission papers of patients with: isolated/multiple somatotropin deficiency (STD), short stature in: renal chronic disease (DRC), small for gestational age (SGA), Turner syndrome (TS) and Prader Willi syndrome (PWS). In adults only isolated somatropin deficiency diagnosed in childhood.
Aims: To analyze the characteristics of patients submitted to the CNNHC from 2006 to 2016.
Methods: Retrospective study of cases submitted to CNNHC for somatotropin (2006–2016). Data collected: demographic, submission date, diagnosis and committee’s decision. Statistic analysis by SPSS21 (P<0.05).
Results: Total submissions n=1968 corresponding to 1909 children/six adults; Males (59.5%) and Females (40.5%). Mainly coming from Pediatric centres (n=1573/80.3%). Submissions increased along time, with a minimum of 87 in 2007 and a maximum of 252 in 2011. Were approved a total of n=1412 (72%) cases: at first submission n=1243 (63.4%) and after reevaluation n=169 (8.6%). Not approved n=535 (27.2%). Diagnostic prevalence: somatotropin deficiency n=1233 (62.9%): isolated n=1067(54.4%) and multiple n=166(8.5%); SGA n=324(16.5%), TS n=177(9%); RCD n=122(6.2%) and PWS n=53(2.7%). Somatotropin deficiency remained the most frequent diagnosis along the years. Age at submission: DRC were submitted earlier (6.4±4.2y), followed by SGA (7.9±3.0y), TS (8.5±3.6y), PWS (9.4±4.0y), multiple STD (9.7±5.1y) and isolated STD (10.3±3.5y). Except from TS, male gender was more frequent at all diagnosis. Were associated with oncologic disease n=182/1968(9.2%): n=97/182(53%) had primary tumours of CNS and n=66/182(36%) due to hemato-oncologic disease (leukemia/lymphoma).
Conclusions: Somatotropin supported treatment in our country has evolved along time, with new approved indications after 2010. The most frequent diagnosis remains isolated somatropin deficiency with a high age at submission witch probably compromises the final stature. We must have more support for deficient somatropin adult patients.
Volume 49
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more